drugset / Trial / NCT03000608
A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis
Phase 2
Completed
69 enrolled
Santalis Pharmaceuticals, Inc.
ClinDatrix, Inc. · collabClinical Trials of Texas, Inc. · collabDerm Research, PLLC · collabDermatology Research Center of San Antonio · collabProgressive Clinical Research · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This trial will be a double-blind, multi-center, randomized, placebo controlled study to evaluate the safety, tolerability, and efficacy of SAN021 study drug when administered for up to 42 days to adults between the ages of 18 to 65 years who have a clinical diagnosis of mild-to-moderate plaque psoriasis.
Timeline
- Start
- 2017-05-17
- Primary completion
- 2017-12-13
- Completion
- 2017-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Essential oils | Unknown | 5 unknown | Topical |